Arcus Biosciences, Inc. (RCUS) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RCUS Revenue Growth
Revenue Breakdown (FY 2025)
RCUS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RCUS Revenue Analysis (2016–2025)
As of May 8, 2026, Arcus Biosciences, Inc. (RCUS) generated trailing twelve-month (TTM) revenue of $236.0 million, reflecting significant decline in growth of -39.3% year-over-year. The most recent quarter (Q1 2026) recorded $17.0 million in revenue, down 48.5% sequentially.
Looking at the longer-term picture, RCUS's 5-year compound annual growth rate (CAGR) stands at +25.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $383.0 million in 2021.
Revenue diversification analysis shows RCUS's business is primarily driven by License And Development Services (87%), Development Services (7%), and R&D Services (3%). With over half of revenue concentrated in License And Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGEN (+10.4% YoY), EXEL (+3.3% YoY), and HALO (+37.6% YoY), RCUS has underperformed the peer group in terms of revenue growth. Compare RCUS vs AGEN →
RCUS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RCUSCurrent | $236M | -39.3% | +25.9% | -156.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
RCUS Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $247.0M | -4.3% | $237.0M | 96.0% | $-386,000,000 | -156.3% |
| 2024 | $258.0M | +120.5% | $258.0M | 100.0% | $-330,000,000 | -127.9% |
| 2023 | $117.0M | +4.5% | $117.0M | 100.0% | $-340,000,000 | -290.6% |
| 2022 | $112.0M | -70.8% | $112.0M | 100.0% | $-280,000,000 | -250.0% |
| 2021 | $383.0M | +391.0% | $383.0M | 100.0% | $54.0M | 14.1% |
| 2020 | $78.0M | +420.0% | $78.0M | 100.0% | $-124,000,000 | -159.0% |
| 2019 | $15.0M | +79.6% | $15.0M | 100.0% | $-88,709,000 | -591.4% |
| 2018 | $8.4M | +491.2% | $8.4M | 100.0% | $-54,859,000 | -656.8% |
| 2017 | $1.4M | - | $1.4M | 100.0% | $-53,441,000 | -3782.1% |
| 2016 | $0 | - | $-1,314,000 | - | $-18,182,000 | - |
See RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRCUS — Frequently Asked Questions
Quick answers to the most common questions about buying RCUS stock.
Is RCUS's revenue growth accelerating or slowing?
RCUS revenue declined -39.3% year-over-year, contrasting with the 5-year CAGR of +25.9%. TTM revenue fell to $236M. This reverses the prior growth trend.
What is RCUS's long-term revenue growth rate?
Arcus Biosciences, Inc.'s 5-year revenue CAGR of +25.9% reflects the variable expansion pattern. Current YoY growth of -39.3% is below this long-term average.
How is RCUS's revenue distributed by segment?
RCUS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.